Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

FDA approval granted for Candela's ALEXlazr

July 19, 1996

Vanguard Medica exercises worldwide rights to VML-262

July 19, 1996

Penederm files FDA amendment regarding Avita

July 19, 1996

Taro's clobetasol propionate approved by FDA

July 19, 1996

Stiefel to develop and market CytoMed's CMI-392

July 19, 1996

OncorPharm acquires rights to dithymidine-based products

July 12, 1996

ProCyte seeks FDA marketing clearance for OsmoCyte

July 12, 1996

FDA issues nonapprovable letter for Avita; development elsewhere on track

July 5, 1996

ProCyte launches Iamin gel in U.S.

July 5, 1996

ICN's Viquin Forte launched in U.S.

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...